|本期目录/Table of Contents|

[1]虞陆超,李海旭,刘孚瑛,等.降钙素缓释剂髓腔内植入对大鼠骨质疏松的影响[J].国际骨科学杂志,2017,02:121-124.
　YU Luchao,LI Haixu,LIU Fuying,et al.The effect of sustained-release salmon calcitonin on rat osteoporosis[J].International Journal of Orthopaedics,2017,02:121-124.
点击复制

降钙素缓释剂髓腔内植入对大鼠骨质疏松的影响(PDF)

《国际骨科学杂志》[ISSN:1673-7083/CN:31-1952/R]

期数:
2017年02期
页码:
121-124
栏目:
实验研究
出版日期:
2017-05-20

文章信息/Info

Title:
The effect of sustained-release salmon calcitonin on rat osteoporosis
作者:
虞陆超; 李海旭; 刘孚瑛; 石文俊; 周强; 石继祥
200333, 上海中医药大学附属普陀医院骨科
Author(s):
YU Luchao;  LI Haixu;  LIU Fuying;  SHI Wenjun;  ZHOU Qiang;  SHI Jixiang
Department of Orthopaedics, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200333, China
关键词:
骨质疏松;  降钙素;  磷酸钙骨水泥;  缓释
Keywords:
Osteoporosis;  Salmon calcitonin;  Calcium phosphate cement;  Sustained-release
分类号:
-
DOI:
10.3969/j.issn.1673-7083.2017.02.013
文献标识码:
-
摘要:
目的 探讨降钙素缓释剂髓腔内植入对大鼠全身骨质疏松的影响。方法 将40只3月龄的雌性SD大鼠随机分为4组,A组为卵巢切除联合低剂量降钙素组,B组为卵巢切除联合高剂量降钙素组,C组为卵巢切除联合空白磷酸钙载体组,D组为假手术组,每组各10只,比较植入术后2、4、8周各组血钙和全身骨密度变化。结果 植入术后8周,与C组相比,A组和B组股骨近端骨密度均有显著改善(P<0.05),A组和B组血钙浓度较C组显著下降(P<0.05)。结论 降钙素缓释剂髓腔内植入可在大鼠体内稳定有效地释放降钙素,降低血钙,提高骨密度。
Abstract:
Objective To evaluate the effect of intramedullary implantation of sustained-release salmon calcitonin on systemic osteoporosis of rats.Methods A total of 40 female SD rats aged 3 months were randomly divided into four groups: ovariectomized rats treated

参考文献/References

[1] 郭世拔,罗先正,邱贵兴. 骨质疏松基础与临床[M]. 天津: 科学技术出版社, 2001:522-531.
[2] Espanol M, Perez RA, Montufar EB, et al. Intrinsic porosity of calcium phosphate cements and its significance for drug delivery and tissue engineering applications[J]. Acta Biomater, 2009, 5(7):2752-2762.
[3] Low KL, Tan SH, Zein SH, et al. Calcium phosphate-based composites as injectable bone substitute materials[J]. J Biomed Mater Res B Appl Biomater, 2010, 94(1):273-286.
[4] Victor SP, Sharma CP. Calcium phosphates as drug delivery systems[J]. J Biomater Tiss Eng, 2012, 2(4):269-279.
[5] Park J, Lee G, Shin US. Self-hardening microspheres of calcium phosphate cement with collagen for drug delivery and tissue engineering in bone repair[J]. J Am Cera Soc, 2011, 94(9):3149.
[6] 陈柏龄,廖威明,李佛保,等. 轻度承重活动对卵巢切除大鼠骨密度组织计量和生物力学的影响[J].中山大学学报(医学科学版), 2001, 22(3):187-191.
[7] Curtis JR, Safford MM. Management of osteoporosis among the elderly with other chronic medical conditions[J]. Drugs Aging, 2012, 29(7):549-564.
[8] Lee HJ, Kim SY, Kim GS, et al. Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans[J]. Osteoporos Int, 2010, 21(8):1351-1360.
[9] Ezzat BA. Validity of prevention of glucocorticoid-induced alveolar bone loss in rat by either calcitonin or alendronate administration[J]. Arch Oral Biol, 2010, 55(10):788-796.
[10] Andresen CJ, Moalli M, Turner CH, et al. Bone parameters are improved with intermittent dosing of vitamin D3 and calcitonin[J]. Calcif Tissue Int, 2008, 83(6):393-403.
[11] Lewiecki EM. Emerging drugs for postmenopausal osteoporosis[J]. Expert Opin Emerg Drugs, 2009, 14(1):129-144.
[12] Tang Y, Singh J. Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies[J]. Pharm Res, 2010, 27(2):272-284.
[13] Binkley N, Bolognese M, Sidorowicz-Bialynicka A, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmeno- pausal osteoporosis(ORACAL)trial[J]. J Bone Miner Res, 2012, 27(8):1821-1829.
[14] Maricic MJ. Oral calcitonin[J]. Curr Osteoporos Rep, 2012, 10(1):80-85.

备注/Memo

备注/Memo:
通信作者: 周强 E-mail: zhouqiang619@aliyun.com
石继祥 E-mail: shijixiang75@sina.com
更新日期/Last Update: 2017-05-20